A Retrospective Analysis of Toxicity Profile in Pediatric Patients with all Receiving High Dose Methotrexete

Abstract

Aims and Objectives: Our aim was to document the toxicity profile in Acute Lymphoblastic Leukemia in pediatric patients who received only chemotherapeutic agent i.e. High Dose Methotrexate in their consolidation phase of their treatment plan. Method: A Retrospective study was carried out in the inpatient department of Aware Gleneagles Global Hospital, Hyderabad, India. A total of 100 pediatric in patients with Acute Lymphoblastic Leukemia from the age of 1-18 years in their Consolidation phase consisting of 4 cycles each containing a course of HDMTX from 2017-2018 were included in the study. All information significant to the study was collected from the Patient case sheets and Electronic medical records in the designed patient's proforma or data collection form which includes Patient demographic details, Laboratory values etc. The information was also retrieved by the telephonic conversation with the patient or patient's representative. Results: In our study mean age was found to be 7.07 ± 4.520.We found that there was high incidence rate in males (67%) than females (33).We observed pediatric patients effected with adverse effects such as nausea and Vomiting (25%), Mucositis (13%), Neutropenia (5%), Anemia (55%), Thrombocytopenia (27%) and Leucopenia (44%). Conclusion: Thus from our study we have concluded that toxicity of High Dose Methotrexate can be minimized to great extent by adequate hydration/ Alkalinization, Leucovorin doses, accurate dose of Anti emetics and frequent monitoring of Urine pH, Serum Creatinine, Complete Blood Count as to detect any toxicity and acute management of the toxicity.